← Eichor
Condition: Nsclc Stage Iiib Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Nsclc Stage Iiib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127Radical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLC
NA · 2 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT07003490A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-L
Phase 3 · 403 location(s) · Amgen · NCT05920356Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Phase 2 · 345 location(s) · National Cancer Institute (NCI) · NCT03191149TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemo
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07330037A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
Phase 3 · 1 location(s) · Beijing Pearl Biotechnology Limited Liability Company · NCT05989542Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
Phase 2 · 2 location(s) · Guangdong Association of Clinical Trials · NCT07120698A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Parti
Phase 3 · 267 location(s) · Merck Sharp & Dohme LLC · NCT06312137A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
Phase 2 · 10 location(s) · Memorial Sloan Kettering Cancer Center · NCT07428044D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage II
Phase 3 · 1 location(s) · Guangdong Provincial People's Hospital · NCT07016126A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
Phase 2 · 1 location(s) · Zhejiang University · NCT05837052A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT05104788Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung
Phase 3 · 1151 location(s) · National Cancer Institute (NCI) · NCT04267848Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Os
Phase 2 · 16 location(s) · Goethe University · NCT05281406MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT05286957Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harbor
Phase 3 · 199 location(s) · Boehringer Ingelheim · NCT07195695Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT06734182Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05295212Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lu
Phase 2 · 21 location(s) · Fundación GECP · NCT07153445SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Phase 3 · 1 location(s) · Nanjing Sanhome Pharmaceutical, Co., Ltd. · NCT06080776Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Phase 2 · 1 location(s) · University Hospital Heidelberg · NCT04865250Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT06659042Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Phase 2 · 97 location(s) · AstraZeneca · NCT05061550Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen
Phase 2 · 13 location(s) · City of Hope Medical Center · NCT07288034Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.
Phase N/A · 1 location(s) · Gene Solutions · NCT06167460A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung C
Phase 3 · 238 location(s) · Merck Sharp & Dohme LLC · NCT06623422Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuv
Phase 2 · 1 location(s) · Wen-zhao ZHONG · NCT07039656A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-s
Phase 3 · 42 location(s) · ETOP IBCSG Partners Foundation · NCT06284317
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.